2023 World Conference on Lung Cancer (Posters)-P2.07. Association of Completing 35 Cycles of Pembrolizumab and Further Progression-Free Survival among Durable Progression-Free Survivors

P2.07. Association of Completing 35 Cycles of Pembrolizumab and Further Progression-Free Survival among Durable Progression-Free Survivors - PDF(Abstract)

Back to course

Pdf Summary

The abstract discusses a study that aimed to determine whether completing the full 35 cycles of pembrolizumab, an immunotherapy drug, is associated with further progression-free survival (PFS) in patients with metastatic non-small cell lung cancer. The researchers extracted PFS and best response data from patients who completed the full 35 cycles of pembrolizumab from four trials with a 5-year follow-up. They found that among the 294 patients who were durable progression-free survivors (dPFSors), 107 did not complete the full 35 cycles and had inferior additional PFS compared to those who completed. Among the 187 dPFSors who completed 35 cycles, they observed a numeric association between response and additional 3-year PFS probability. Patients who had a complete response had a higher probability compared to those with a partial response or stable disease. The study suggests that not completing the full 35 cycles of pembrolizumab, usually due to toxicity, may negatively impact long-term oncological outcomes, despite having similar disease control for more than 2 years. Further research is needed to explore this relationship.

Asset Subtitle

Lei Deng

Meta Tag

Speaker Lei Deng

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

pembrolizumab

immunotherapy drug

metastatic non-small cell lung cancer

progression-free survival

PFS

best response

durable progression-free survivors

complete response

partial response

stable disease